3 - Level 3 (INTERMEDIATE)

Marina Cuchel, MD, PhD presented Genetics of Familial Hypercholesterolemia. Dr. Cuchel discuss FH (Familial Hypercholesterolemia), the underlying genetic defects that cause FH, and how the molecular basis of FH affects lipid lowering treatment.

5
Average: 5 (1 vote)

John R. Guyton, M.D. presented Niacin's Triple Paradox and Thoughts on HDL. Dr. Guyton discusses the three paradox of Niacin.

5
Average: 5 (1 vote)

Dr. Terry A. Jacobson discusses Omega 3's and cardiovascular disease, high versus low dose.

5
Average: 5 (1 vote)

Dr. Benjamin Ansell discusses, HDL, the state of lipoprotein. Topics include understanding HDL structure and function and how HDL functionality may be more relevant than current HDL testing.

5
Average: 5 (1 vote)

Keynote Speaker, Dr. William Virgil Brown, MD, FNLA, presented Guidelines for Lipid Management in 2014.

4.5
Average: 4.5 (2 votes)

Eliot A. Brinton, MD, FNLA presents his talk on  Clinical Management of Hypertriglyceridemia: State of the Art 2015.

5
Average: 5 (1 vote)

Carl E. Orringer, MD, FNLA presents his talk on Two Different Prevention Approaches Two Different Perspectives.

5
Average: 5 (1 vote)

The NLA is pleased to announce a NEW online CME/CE activity entitled, The Emergent Science of HDL and its Metabolism: Mechanistic Understanding of CETP Antagonism and Beyond. This NLA- and Rockpointe-endorsed activity includes selected presentations and expert faculty commentary from the satellite... more

5
Average: 5 (1 vote)

Allan D. Sniderman, MD presents his talk on ApoB in Risk Assessment and the Diagnosis and Treatment of the Atherogenic Dyslipoproteinemias.

5
Average: 5 (2 votes)

This special symposium was held at the 2013 NLA Annual Scientific Sessions this past May in Las Vegas, NV with audio and slide highlights captured for additional viewing. This activity defines HoFH and discusses the marked cardiovascular risk associated with this diagnosis. Please join our... more

5
Average: 5 (1 vote)